CN104513297A - Polypeptide molecule for screening anti-cancer pharmaceutical composition and application thereof - Google Patents
Polypeptide molecule for screening anti-cancer pharmaceutical composition and application thereof Download PDFInfo
- Publication number
- CN104513297A CN104513297A CN201410417537.8A CN201410417537A CN104513297A CN 104513297 A CN104513297 A CN 104513297A CN 201410417537 A CN201410417537 A CN 201410417537A CN 104513297 A CN104513297 A CN 104513297A
- Authority
- CN
- China
- Prior art keywords
- seq
- sequence
- antibody
- peptide molecule
- transport protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 96
- 229920001184 polypeptide Polymers 0.000 title abstract description 37
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 37
- 238000012216 screening Methods 0.000 title abstract description 16
- 230000001093 anti-cancer Effects 0.000 title abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 111
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 106
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims abstract description 30
- 230000027455 binding Effects 0.000 claims abstract description 21
- 210000004027 cell Anatomy 0.000 claims description 91
- 206010028980 Neoplasm Diseases 0.000 claims description 84
- 201000011510 cancer Diseases 0.000 claims description 84
- 239000000203 mixture Substances 0.000 claims description 45
- 210000002381 plasma Anatomy 0.000 claims description 33
- 239000000523 sample Substances 0.000 claims description 29
- 210000000822 natural killer cell Anatomy 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 18
- 239000002246 antineoplastic agent Substances 0.000 claims description 16
- 229940127089 cytotoxic agent Drugs 0.000 claims description 15
- 239000000725 suspension Substances 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 14
- 239000011324 bead Substances 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 11
- 231100000167 toxic agent Toxicity 0.000 claims description 11
- 239000003440 toxic substance Substances 0.000 claims description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 4
- 230000001629 suppression Effects 0.000 claims description 4
- 238000000018 DNA microarray Methods 0.000 claims description 3
- 238000001262 western blot Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 35
- 231100000572 poisoning Toxicity 0.000 abstract description 6
- 230000000607 poisoning effect Effects 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract 1
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 229930184591 Fringelite Natural products 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 231100000331 toxic Toxicity 0.000 description 10
- 230000002588 toxic effect Effects 0.000 description 10
- 239000000872 buffer Substances 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000031700 light absorption Effects 0.000 description 5
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 description 3
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 3
- 206010048723 Multiple-drug resistance Diseases 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 2
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 2
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101000956263 Homo sapiens Uncharacterized protein C19orf48 Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102100038573 Uncharacterized protein C19orf48 Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002277 temperature effect Effects 0.000 description 2
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 102100037128 ATP-binding cassette sub-family C member 10 Human genes 0.000 description 1
- 102100028161 ATP-binding cassette sub-family C member 2 Human genes 0.000 description 1
- 102100028162 ATP-binding cassette sub-family C member 3 Human genes 0.000 description 1
- 102100028282 Bile salt export pump Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 240000004272 Eragrostis cilianensis Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101001029059 Homo sapiens ATP-binding cassette sub-family C member 10 Proteins 0.000 description 1
- 101000986633 Homo sapiens ATP-binding cassette sub-family C member 3 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000969812 Homo sapiens Multidrug resistance-associated protein 1 Proteins 0.000 description 1
- 101000955481 Homo sapiens Phosphatidylcholine translocator ABCB4 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 108010093662 Member 11 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010066419 Multidrug Resistance-Associated Protein 2 Proteins 0.000 description 1
- 102000011279 Multidrug resistance protein 1 Human genes 0.000 description 1
- 102100039032 Phosphatidylcholine translocator ABCB4 Human genes 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 240000006413 Prunus persica var. persica Species 0.000 description 1
- 108010091128 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 1
- 102000018066 Subfamily G ATP Binding Cassette Transporter Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013400 design of experiment Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940098197 human immunoglobulin g Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 102000004233 multidrug resistance protein 3 Human genes 0.000 description 1
- 108090000743 multidrug resistance protein 3 Proteins 0.000 description 1
- 108010066052 multidrug resistance-associated protein 1 Proteins 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
Abstract
The invention provides at least one polypeptide molecule for detecting the content of ATP binding cassette transport protein antibody in a sample, and further screening the sample rich in the ATP binding cassette transport protein antibody as an anti-cancer pharmaceutical composition for poisoning drug-resistant cancer cells.
Description
[technical field]
System of the present invention about one for screening peptide molecule and the application thereof of anticancer medical composition, particularly about one for screening peptide molecule and the application thereof of atp binding cassette transport protein antibody (anti-ATPbinding-cassette transporter antibody).
[background technology]
Chemotherapy is the primary treatments of middle and terminal cancer.Generally speaking, cancer patient is after chemotherapy after a while, although most cancer cells all can be dead, still have minority can not retained in vivo by the successful cancer cells of poisoning, quantity is about 10
8~ 10
9between.Those cancer cells retained can show a large amount of atp binding cassette transport protein (ATP binding-cassette transporter, hereinafter referred to as ABC transport protein), and ABC transport protein is transported on cytolemma, to perform the work getting rid of intracellular chemistry medicine.That is the cancer cells of retention can utilize ABC transport protein that the chemotherapeutic agent in cancer cells is transferred to extracellular, therefore, chemotherapeutic agent no longer effectively can attack those cancer cells retained.This i.e. so-called cancer cells resistance clinically.The method of urgently looking for beyond chemotherapy is killed those and is had drug-fast cancer cells.
Document
sarkadi B,
homolya L,
szak á cs G,
v á radi A.Human multidrugresistance ABCB and ABCG transporters:participation in a chemoimmunitydefense system.
physiol Rev.2006, mention the ABC transport protein relevant with cancer cells resistance in 86 (4): 1179-1236, mainly comprise following subfamily:
Atp binding cassette transport protein subfamily B (ATP-binding cassette proteinsubfamily B): such as ABCB1, be also called multiple drug resistance albumen 1 (multi drug resistanceprotein 1, be called for short MDR1), be also called P glucoprotein (permeability glycoprotein); Such as ABCB4 (being also called MDR3) again; Also having such as ABCB11 in addition, is the homology family (Sister ofPgp) of Pgp.
Atp binding cassette transport protein subfamily C (ATP-binding cassette proteinsubfamily C): such as ABCC1, be also called multiple drug resistance associated protein 1 (multi drug resistancerelated protein 1 is called for short MRP1); Such as ABCC2 again, is also called multiple drug resistance associated protein 2 (multi drug resistance related protein 2 is called for short MRP2); Also may comprise ABCC3 – 6, ABCC10 – 11.
Atp binding cassette transport protein subfamily G (ATP-binding cassette proteinsubfamily G): such as ABCG2, be also called two fringelite drug resistance protein (mitoxantroneresistance protein, be called for short MXR), also breast cancer drug resistance protein (breast cancer resistanceprotein is called for short BCRP) is called.
US Patent No. 7785812 describes a kind of method of killing resistant cancer cells, is to utilize to show that a large amount of ABC transport proteins on resistant cancer cells surface carry out target attack.It manufactures ABC transport protein antibody (anti-ATP binding-cassette transporter antibody) in artificial mode, and utilizes this ABC transport protein antibody to carry to be enough to the medicine of killing cell, forms an antibody target medicine.Then, this antibody target medicine is combined on resistant cancer cells by ABC transport protein antibody, and around resistant cancer cells, carries out toxic action with the medicine entrained by it.
But, no matter be again in order to screen ABC transport protein antibody after directly preparing ABC transport protein antibody or first preparing ABC transport protein, the process wherein preparing ABC transport protein antibody/ABC transport protein all must consider whether it can be folded into correct configuration, the factor will considered in preparation is difficult and complicated, makes cost be difficult to reduce.In addition, according to the ABC transport protein antibody manufactured by prior art, only can identification single kind of ABC transport protein, be difficult to the resistant cancer cells being applicable to all kinds.Moreover prior art utilizes medicine to resist property of medicine cancer cells and kills, and gets off for a long time, will cause no small burden to health and kidney.
[summary of the invention]
Because the defect of prior art, the invention provides the peptide molecule that a kind of processing procedure is simple, to replace the ABC transport protein of complex structure, as the Main Basis of screening ABC transport protein antibody.
In addition, the invention provides multiple polypeptides molecule and combination thereof, the enable medical composition filtered out containing multiple ABC transport protein antibody, and various different types of resistant cancer cells can be applicable to.
The present invention also provides a kind of and bears less cancer medical composition, to resist resistant cancer cells to health and kidney.
The present invention reoffers a kind of cancer medical composition, can promote the whole capability of natural killer cell toxicant killing cancer cell.
The present invention more provides a kind of cancer medical composition, can solve the resistance problems of resistant cancer cells, and then act synergistically with chemotherapeutic agent, suppresses the quantity of resistant cancer cells.
In a preferred embodiment, the invention provides a kind of peptide molecule, the aminoacid sequence of this peptide molecule comprises at least one in SEQ ID NO:1 sequence, SEQ ID NO:2 sequence, SEQ ID NO:3 sequence, SEQID NO:4 sequence, SEQ ID NO:5 sequence, SEQ ID NO:6 sequence and SEQ ID NO:7 sequence or its combination.
In a preferred embodiment, this peptide molecule can combine with the antibody of at least one atp binding cassette transport protein (anti-ATP binding-cassette transporter antibody).
The present invention also provides a kind of purposes of peptide molecule, for filtering out a cancer medical composition, wherein the aminoacid sequence of this peptide molecule comprises at least one in SEQ ID NO:1 sequence, SEQ ID NO:2 sequence, SEQ ID NO:3 sequence, SEQ ID NO:4 sequence, SEQ ID NO:5 sequence, SEQ ID NO:6 sequence and SEQ ID NO:7 sequence or its combination.
In a preferred embodiment, for filtering out this cancer medical composition from separation in one of human body blood, a blood plasma or a serum.
In a preferred embodiment, in this cancer medical composition, comprise the antibody of at least one atp binding cassette transport protein.
In a preferred embodiment, this cancer medical composition can promote the effect of natural killer cell toxicant killing cancer cell.
In a preferred embodiment, this cancer medical composition can act synergistically with chemotherapeutic agent, suppresses the quantity of resistant cancer cells.
The present invention provides a kind of in addition and is separated the antibody of (or purifying) or the antibody of artificial production, can be combined with peptide molecule as described below:
Comprise the peptide molecule of at least one in SEQ ID NO:1 sequence, SEQ ID NO:2 sequence, SEQ ID NO:3 sequence, SEQID NO:4 sequence, SEQ ID NO:5 sequence, SEQ ID NO:6 sequence and SEQ ID NO:7 sequence or its combination.
In a preferred embodiment, the effect of natural killer cell toxicant killing cancer cell can be promoted.
In a preferred embodiment, can act synergistically with chemotherapeutic agent, suppress the quantity of resistant cancer cells.
The present invention more provides a kind of and detects cover group, in order to detect antibody (the anti-ATP binding-cassette transporter antibody) content of the atp binding cassette transport protein in sample; Comprise a peptide molecule in this detection cover group, and the aminoacid sequence of this peptide molecule comprises at least one in SEQ ID NO:1 sequence, SEQID NO:2 sequence, SEQ ID NO:3 sequence, SEQ ID NO:4 sequence, SEQ ID NO:5 sequence, SEQ ID NO:6 sequence and SEQ ID NO:7 sequence or its combination.
In a preferred embodiment, the invention provides a kind of detection method, system is using a peptide molecule as a probe, detect antibody (the anti-ATPbinding-cassette transporter antibody) content of the atp binding cassette transport protein in a sample, wherein the aminoacid sequence of this peptide molecule comprises at least one in SEQ ID NO:1 sequence, SEQ ID NO:2 sequence, SEQ ID NO:3 sequence, SEQ ID NO:4 sequence, SEQ ID NO:5 sequence, SEQ ID NO:6 sequence and SEQ ID NO:7 sequence or its combination.
In a preferred embodiment, system utilizes at least one of ferment immunoabsorption, Western blot, biochip method, Beads enrichment and quantitative manner and other probe in detecting modes, detects the anti-body contg of the atp binding cassette transport protein in this sample.
In a preferred embodiment, it at least comprises the following steps:
In coating (coating) this peptide molecule to one container;
One of to remove in this container the first suspension;
Insert one of this sample proper concn sample in this container;
One of to remove in this container the second suspension;
Insert a second antibody;
One of to remove in this container the 3rd suspension; And
Detect the content of this second antibody in this container.
In a preferred embodiment, this container system 96 porose disc.
In a preferred embodiment, this sample system is separated at least one in one of human body blood, a blood plasma or a serum.
[accompanying drawing explanation]
Fig. 1: be a block flow diagram, indicates the application and detects one of ABC transport protein anti-body contg embodiment of the method.
Fig. 2: be that cancer medicine blood plasma is on the histogram of the impact of cancer cells resistance.
Fig. 3: be that cancer medicine blood plasma is on the histogram of the impact of natural killer cell toxicant killing cancer cell.
Fig. 4: be a block flow diagram, indicates and utilizes one of the application's peptide molecule purifying ABC transport protein antibody embodiment of the method.
[embodiment]
In view of restriction and the defect of prior art, the invention provides peptide molecule and the application method thereof of at least one screening cancer medical composition, be the medical composition being rich in antibody with the simple peptide molecule screening of configuration, and utilize this medical composition to reach the effect of poisoning resistant cancer cells.
Known natural killer cell (Natural killer cells; Be generally defined as CD3-CD56
+the lymphocyte of subgroup) on human immune system, play the part of key player to inhibiting tumor cell, the cell toxic action (antibody-dependent cell-mediated cytotoxicity is called for short ADCC) that main system is mediated by antibody dependent cellular kills cancer cells.In detail, when cancer cells performance ABC transport protein (thus there is resistance), and during by ABC transport protein antibodies next in or beyond health, the CD16 molecule [FcgR III of natural killer cell surface; It is the acceptor of antibody constant region (fragment of constant region), understand the constant region that specificity is incorporated into everyone antibody-like] understand identification and combine with the constant region (constant region of such as IgG antibody) of this ABC transport protein antibody, then cause the cell toxic action (hereinafter referred to as ADCC effect) of the antibody dependent cellular mediation of natural killer cell, the cytokines such as release interferon gamma (IFN-γ) kill this resistant cancer cells.
According to contriver's experience for many years and result of study, think and should be able to capture the advantage that prior art is target with ABC transport protein, removal need be prepared the antibody/protein of configuration complexity and need utilize two kinds of shortcomings such as medicine poisoning, develops a kind of easier, method to the less poisoning resistant cancer cells of body burden.That is, research and develop a kind of linear polypeptide antigen, to screen the medical composition containing multiple ABC transport protein antibody.ABC transport protein antibody in this medical composition can be combined with the ABC transport protein on resistant cancer cells surface, form target, and this ABC transport protein antibody capable causes the ADCC effect of natural killer cell, makes natural killer cell kill those resistant cancer cells.In addition, if contriver thinks linear polypeptide, ANTIGEN DESIGNThe is proper, ABC transport protein antibody in the medical composition filtered out should be able to block the function of ABC transport protein simultaneously, suppress resistant cancer cells to be transferred to outside born of the same parents by chemotherapeutic agent, and then solve the resistance problems of resistant cancer cells.
Be below the circumstantial letter that the embodiment utilizing the present invention is provided, and the technology of the present invention and feature.Right the present embodiment is also not used to limit the present invention, is anyly familiar with this operator, without departing from the spirit and scope of the invention the various change that completes or retouching, all should be contained in the claim of the application.
The design of experiment one: ABC transport protein linear polypeptide molecule
Utilize bioinformatics method, from various ABC transport protein (referring to cause the drug-fast ABC transport protein of chemotherapy) sequence, look for and human leukocyte antigens (Human leukocyte antigen, abbreviation HLA; The i.e. Major histocompatibility complex of the mankind, is called for short MHC) there is the sequence location of higher affinity.The linear peptide sequence found out in this approach comparatively just may be positioned at ABC transport protein surface, and can replace ABC transport protein, in specific manner with ABC transport protein antibodies.
Improvement and experiment screening is designed through a series of, (peptide molecule is generally made up of 20 ~ 50 amino acid to develop 7 kinds of ABC transport protein linear polypeptide molecules, but not as limit), i.e. SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ IDNO:6 and SEQ ID NO:7.These 7 kinds of ABC transport protein linear polypeptide molecules or its combination, all can combine with the antibody of at least one ABC transport protein (anti-ATP binding-cassette transporterantibody), and can filter out cancer medical composition.Especially, these 7 kinds of ABC transport protein linear polypeptide molecules or its combination, all similar to epitope (epitope) configuration of the ABC transport protein of at least one cause cancer chemotherapeutic agent resistance, therefore the antibodies of the ABC transport protein of chemotherapeutic agent resistance can be caused with those, to filter out the cancer medical composition that can resist resistant cancer cells.
Wherein, the bonding force between the antibody of those ABC transport protein linear polypeptide molecules and this at least one ABC transport protein, (Phosphate Buffered Saline, is called for short PBS to be greater than phosphate buffered saline buffer; PH7.4) bonding force and between the antibody of this at least one ABC transport protein.
Experiment two: preparation ABC transport protein linear polypeptide molecule
Synthesize those ABC transport protein linear polypeptide molecules with chemical method, purity must be greater than 95%.Victory peptide symthesis service company can be entrusted to synthesize those ABC transport protein linear polypeptide molecules.Applicant entrusts (address: 1 of 10th floor, No. 3, garden street, Nan Gang district of Taibei city, Ming Xin bio tech ltd; Phone: 02-26557128; Network address: http://www.missionbio.com.tw/) prepare this 7 kinds of ABC transport protein linear polypeptide molecules.
The ABC transport protein linear polypeptide molecule of synthesis is dissolved in (67% acetic acid of 5mg linear polypeptide molecule/1mL) in the acetic acid of 67%, preserves in the cryogenic refrigerator of-20 DEG C.
Experiment three: screening cancer medical composition
At least one of above-mentioned 7 kinds of ABC transport protein linear polypeptide molecules is mixed with sample (being such as separated at least one in one of human body blood, a blood plasma or a serum), detects the content of ABC transport protein linear polypeptide molecule-ABC transport protein antibody complex (hereinafter referred to as peptide molecule-antibody complex) in sample.Peptide molecule-more person of antibody complex content, represent the antibody containing a large amount of ABC transport protein in raw sample, can be used as cancer medical composition, to cause the cell toxic action (antibody-dependent cell-mediated cytotoxicity) of the antibody dependent cellular mediation of natural killer cell, kill the resistant cancer cells of performance ABC transport protein.
Wherein, ferment immunoabsorption (Enzyme-linked immunosorbent assay can be utilized, be called for short ELISA) or other detection modes utilizing peptide molecule to be probe (such as Western blot, biochip method, Beads enrichment and quantitative manner), detect the content of ABC transport protein antibody in sample, the sample of cancer medical composition is suitable as, the cancer medical composition of the antibody of the ABC transport protein espespecially containing at least one cause cancer chemotherapy resistance with screening.Be described in detail for ferment immunoabsorption below:
Refer to Fig. 1, it is a block flow diagram, indicates the application and detects one of ABC transport protein anti-body contg embodiment of the method.The better implementation method of a kind of ABC of detection of the present invention transport protein anti-body contg at least comprises:
Step S1: in coating peptide molecule to container;
Step S2: one of to remove in this container the first suspension;
Step S3: insert one of sample proper concn sample in this container;
Step S4: remove one second suspension in this container;
Step S5: insert a second antibody;
Step S6: remove 1 in this container the 3rd suspension; And
Step S7: the content detecting this second antibody in this container.
In this preferred embodiment, this container in step S1 is 96 porose discs.In one first hole that step S1 ties up to 96 porose discs and one second hole, add the ABC transport protein linear polypeptide molecule of 100 μ L, and in one the 3rd hole and one the 4th hole of 96 porose discs, add the vegetable protein peptide molecule of 100 μ L, 4 DEG C of coatings, 8 hours (or spending the night).
Wherein, first with phosphate buffered saline buffer, (Phosphate Buffered Saline, is called for short PBS for this ABC transport protein linear polypeptide molecule and this vegetable protein peptide molecule; PH 7.4) be diluted to 5 ~ 20 μ g/mL.And this ABC transport protein linear polypeptide divides subsystem SEQ ID NO:1, SEQ ID NO:2, SEQ IDNO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7 to mix gained with equal proportion.
To apply this first hole of ABC transport protein linear polypeptide molecule for experimental group, 3rd hole of coating vegetalitas peptide molecule is control group, this second hole of coating ABC transport protein linear polypeptide molecule is the first blank group, and the 4th hole of coating vegetalitas peptide molecule is the second blank group.
Moreover the first suspension in this first hole, the second hole, the 3rd hole, the 4th hole is removed by step S2 system.Preferably, after removing the first suspension, then with phosphate buffered saline buffer (pH 7.4) cleaning three times.
In addition, this sample system in step S3 is separated from one of human body blood plasma (also replaceable is a blood, a serum, but not as limit).This this blood plasma of proper concn sample system (or this blood, this serum, but not as limit) made by after phosphate buffered saline buffer (pH 7.4) dilution 100 ~ 200 times.In step S3, lie in this first hole and the 3rd hole and add this proper concn sample of 100 μ L, then add 100 μ L phosphate buffered saline buffers (pH 7.4) in this second hole and the 4th hole, and act on for some time under proper temperature.Preferably, in room temperature effect 2 hours.
The second suspension in this first hole, the second hole, the 3rd hole, the 4th hole is removed by step S4 system.Preferably, after removing the second suspension, then with phosphate buffered saline buffer (pH 7.4) cleaning three times.
The antibody that this second antibody system in step S5 can be combined with mankind ABC transport protein antibody specificity, such as rabbit human immunoglobulins G antibody (
anti-Human IgG (Fc specific) antibody produced in rabbit) or goat anti-human immunoglobulin G antibody (
anti-Human IgG (Fc specific) antibody produced ingoat).In step S5, be this second antibody (such as with phosphate buffered saline buffer (pH 7.4) dilution 10000 times) adding such as 200 μ L proper concns, and act on for some time under proper temperature.Preferably, in room temperature effect 2 hours.
The 3rd suspension in this first hole, the second hole, the 3rd hole, the 4th hole is removed by step S6 system.Preferably, after removing the 3rd suspension, then with phosphate buffered saline buffer (pH 7.4) cleaning three times to five times.
The Cleaning Principle of step S7, it is the ferment utilizing this second antibody to carry, one compound is converted to a colour generation compound, then the content of this second antibody and the amount of this ferment and the colour generation depth proportional, the content of this second antibody can be pushed back by detecting shade.Preferably, this ferment that this second antibody is carried, can be converted to blue product by tetramethyl benzidine (Tetramethylbenzidine is called for short TMB).Or the Cleaning Principle of step S7, is that the fluorescent substance utilizing this second antibody to carry detects, pushes back the content of this second antibody by fluorescence intensity.
In this preferred embodiment, the concrete steps of step S7 lie in this first hole, the second hole, the 3rd hole, the 4th hole and add 100 μ L TMB, react 20 minutes, then add 50 μ L 2M H
2sO
4termination reaction.Take 450nm as determined wavelength, 630nm is reference wavelength, measures light absorption value (OD value), and calculates specific binding index (specific binding index is called for short SBI):
SBI=(light absorption value of light absorption value-the first blank group of experimental group)/(light absorption value of light absorption value-the second blank group of control group)
(at least one from one of human body blood, a blood plasma or a serum is such as separated as screening sample using SBI, but not as limit) referential data, every ratio is greater than 1.5, can be used as the cancer medical composition of Therapeutic cancer, for guiding natural killer cell it " cell toxic action (i.e. ADCC effect) of antibody dependent cellular mediation ".In described cancer medical composition, the blood that SBI value is greater than 1.5, is called cancer medicine blood; The blood plasma that SBI value is greater than 1.5, is called cancer medicine blood plasma; The serum that SBI value is greater than 1.5, is called cancer medicine serum.
Experiment four: the effect of test cancer medical composition
(1) screening has the drug-fast JEG-3 of chemotherapeutic agent
Plant in 24 porose discs (24well) into the strain of MCF-7 breast cancer cell, cell concn is 5 × 10
4/ mL.(i.e. Mitoxantrone is a kind of chemotherapeutic agent to add the two fringelite of 100nM; Can purchased from American Sigma-Aldrich company, name of product be Mitoxantrone dihydrochloride) succeeding transfer culture one month, the cell of survival is the MCF-7 breast cancer cell with two fringelite resistance.
(2) cancer medical composition is on the impact of cancer cells resistance
In 96 porose discs (96well), planting the MCF-7 breast cancer cell into having two fringelite resistance, making in every hole containing 5000 cells.Add the two fringelite of 100nM in control group to cultivate.The two fringelite of 100nM and 5% cancer medicine blood plasma (being added in 95 μ L enchylema by 5 μ L cancer medicine blood plasma) is added, co-cultivation in experimental group.In cultivation after 24,48,72 hours, detect with MTT Analysis on Biological Activity method (MTT assay) and calculate cell survival rate.
Wherein, the ABC transport protein linear polypeptide molecule for screening this cancer medicine blood plasma comprises this case 7 kinds of ABC transport protein linear polypeptide molecules.That is, be seven kinds of ABC transport protein linear polypeptide molecules of SEQ ID NO:1, SEQID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7 by aminoacid sequence, with equal proportion mixing, obtain ABC transport protein linear polypeptide molecule mixture.Recycling ABC transport protein linear polypeptide molecule mixture filters out the blood plasma that SBI value is greater than 1.5, obtains this cancer medicine blood plasma.
Refer to Fig. 2, for cancer medicine blood plasma is on the histogram of the impact of cancer cells resistance.In Fig. 2, left side group adds the control group of two fringelite, and right side group is then the experimental group of adding two fringelite and cancer medicine blood plasma co-cultivation.Cellular control unit is after cultivating 1 day, 2 days, 3, and cell quantity reaches 6.4 × 10 respectively
3individual cells/well, 9.4 × 10
3individual cells/well, 12.9 × 10
3individual cells/well.Experimental group cell is after cultivating 1 day, 2 days, 3 days, and cell quantity reaches 4.0 × 10 respectively
3individual cells/well, 4.8 × 10
3individual cells/well, 6.2 × 10
3individual cells/well, all has significant difference (p<0.001) with between the control group cultivating same time span.
Fig. 2 shows the MCF-7 breast cancer cell that cancer medicine blood plasma can suppress to have two fringelite resistance and grows, and inhibition is with length and increasing action time.Wherein, reach 37.5% with the suppression ratio of cancer medicine blood plasma effect after 1 day, the suppression ratio after 2 days that acts on reaches 48.9%, and the suppression ratio after 3 days that acts on reaches 51.9%.
Accordingly, the cancer medicine blood plasma filtered out with the present invention's 7 kinds of ABC transport protein linear polypeptide molecules, there is high density ABC transport protein antibody, can be combined with the ABC transport protein on resistant cancer cells surface, and then chemotherapeutic agent is transferred to the path outside born of the same parents by blocking-up resistant cancer cells, make chemotherapeutic agent can continue to play the effect of anticancer growth.Therefore, utilize the cancer medical composition that the present invention's 7 kinds of ABC transport protein linear polypeptide molecules filter out, contribute to the resistance problems solving resistant cancer cells, and can act synergistically with chemotherapeutic agent, significantly suppress the quantity of resistant cancer cells.
(3) cancer medical composition is on the impact of natural killer cell toxicant killing cancer cell
In 96 porose discs (96well), planting the MCF-7 breast cancer cell into having two fringelite resistance, making in every hole containing 5000 cells.In control group, every hole adds 2 × 10
4individual natural killer cell co-culture.In experimental group, every hole adds 2 × 10
4individual natural killer cell and 5% cancer medicine blood plasma (5 μ L cancer medicine blood plasma are added in 95 μ L cell mixing liquid), co-cultivation.In cultivation after 24,48,72 hours, detect with MTT Analysis on Biological Activity method (MTT assay) and calculate the survival rate of MCF-7 breast cancer cell.
Wherein, the ABC transport protein linear polypeptide molecule for screening this cancer medicine blood plasma comprises this case 7 kinds of ABC transport protein linear polypeptide molecules.That is, be seven kinds of ABC transport protein linear polypeptide molecules of SEQ ID NO:1, SEQID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7 by aminoacid sequence, with equal proportion mixing, obtain ABC transport protein linear polypeptide molecule mixture.Recycling ABC transport protein linear polypeptide molecule mixture filters out the blood plasma that SBI value is greater than 1.5, obtains this cancer medicine blood plasma.
Refer to Fig. 3, for cancer medicine blood plasma is on the histogram of the impact of natural killer cell toxicant killing cancer cell.In Fig. 3, left side group adds the control group of natural killer cell, and right side group is then the experimental group of adding natural killer cell and cancer medicine blood plasma co-cultivation.Cellular control unit is after cultivating 1 day, 2 days, 3 days, and cell quantity reaches 4.5 × 10 respectively
3individual cells/well, 5.9 × 10
3individual cells/well, 8.5 × 10
3individual cells/well.Experimental group cell is after cultivating 1 day, 2 days, 3, and cell quantity then reaches 3.1 × 10 respectively
3individual cells/well, 3.5 × 10
3individual cells/well, 5.0 × 10
3individual cells/well, all has significant difference (p<0.001) with between the control group cultivating same time span.
Fig. 3 shows cancer medicine blood plasma significantly can promote the tumoricidal effect of natural killer cell toxicant, and effect increases with work length action time.Wherein, promote 31.1% with the cancer medicine blood plasma effect toxic effect of 1 day, the toxic effect acting on 2 days promotes 40.7%, acts on the toxic effect after 3 days and promotes 41.2%.
Accordingly, the cancer medicine blood plasma filtered out with the present invention's 7 kinds of ABC transport protein linear polypeptide molecules, there is high density ABC transport protein antibody, the cell toxic action (antibody-dependent cell-mediated cytotoxicity) of the antibody dependent cellular mediation of natural killer cell can be caused, the whole structure of natural killer cell toxicant killing cancer cell is promoted, significantly reduces the quantity of resistant cancer cells.
According to the present inventor's experience for many years and invention result of study, when using the medical composition of the present invention in animal body, suggestion each chemistry inputs this medical composition of 150 ~ 300mL once the course for the treatment of.
Experiment five: purifying ABC transport protein antibody
Refer to Fig. 4, it is a block flow diagram, indicates and utilizes one of the application's peptide molecule purifying ABC transport protein antibody embodiment of the method.
Step S11: prepare with one of peptide molecule magnetic bead, forms a magnetic bead peptide molecule;
Step S12: mix this magnetic bead peptide molecule and a sample, and obtain a mixed solution;
Step S13: by this mixed solution by receiving one of magnetic force tubing string (column);
Step S14 a: damping fluid is injected this tubing string, to be separated this magnetic bead peptide molecule in a magnetic bead peptide molecule and antibody complex and an ABC transport protein antibody.
Wherein, at least one in this peptide molecule system SEQ ID NO:1 in step S11, SEQ ID NO:2, SEQID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7.Step S11 can entrust magnetic bead manufacturer on behalf of execution, such as, entrust Taiwan round dot Nai meter technical concern company limited (address: No. 2, Lane 12, lane, Long Shou street 81, Taoyuan County peach garden city; Phone: 03-3607555; Network address: http://www.tanbead.com/) on behalf of execution.
In step S12, with magnetic bead peptide molecule and an antibody complex in this mixed solution.
Perform in the process of step S13, this magnetic bead peptide molecule in this mixed solution and antibody complex can be adsorbed on this tubing string by magnetic influence.
In step S14, this damping fluid should select the connection relationship person that can interrupt this magnetic bead peptide molecule and this ABC transport protein antibody.If step S11 entrusts magnetic bead manufacturer to carry out, then this manufacturer can provide suitable damping fluid in the lump.
The ABC transport protein antibody of purifying in this way, can cause the cell toxic action of the antibody dependent cellular mediation of natural killer cell, and can be further used for preparing cancer drug or preparation cancer medical composition.
Comprehensive the above, the application provides 7 kinds of ABC transport protein linear polypeptide molecules, can filter out cancer medicine blood, cancer medicine blood plasma, cancer medicine serum or be purified into the various cancer medical compositions such as ABC transport protein antibody.Described cancer medical composition can make the whole structure of natural killer cell toxicant killing cancer cell promote, and also can solve the resistance problems of resistant cancer cells, and then makes chemotherapeutic agent play the effect of poisoning resistant cancer cells.
The one that the application provides is for screening at least one in the peptide molecule of anticancer medical composition and SEQ IDNO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7, also or, a kind of peptide molecule be made up of 20 ~ 50 amino acid, its sequence comprises at least one in SEQ ID NO:1, SEQ ID NO:2, SEQID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7.
What will be understood that is, a kind of derivative peptide molecule, system the sequence be defined in SEQ ID NO:1, SEQ IDNO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7 carried out the replacement of one or more amino acid, deletion or after adding derive, and can with the antibodies person of at least one atp binding cassette transport protein, also should be contained in the claim of the application.
The foregoing is only the preferred embodiment of the present invention, and be not used to limit the claim of the present invention, therefore all other does not depart from various change that lower of disclosed spirit completes or retouching etc., all should be contained in the claim of the application.
Claims (16)
1. a peptide molecule, its aminoacid sequence comprises at least one in SEQ ID NO:1 sequence, SEQ ID NO:2 sequence, SEQ ID NO:3 sequence, SEQ ID NO:4 sequence, SEQ ID NO:5 sequence, SEQ ID NO:6 sequence and SEQ ID NO:7 sequence or its combination.
2. peptide molecule as claimed in claim 1, this peptide molecule can with the antibodies of at least one atp binding cassette transport protein.
3. the purposes of a peptide molecule, for filtering out a cancer medical composition, wherein the aminoacid sequence of this peptide molecule comprises at least one in SEQ ID NO:1 sequence, SEQ ID NO:2 sequence, SEQ ID NO:3 sequence, SEQ ID NO:4 sequence, SEQ ID NO:5 sequence, SEQ ID NO:6 sequence and SEQ ID NO:7 sequence or its combination.
4. the purposes of peptide molecule as claimed in claim 3, for filtering out this cancer medical composition from separation in one of human body blood, a blood plasma or a serum.
5. the purposes of peptide molecule as claimed in claim 3, comprises the antibody of at least one atp binding cassette transport protein in this cancer medical composition.
6. the purposes of peptide molecule as claimed in claim 5, this cancer medical composition can promote the effect of natural killer cell toxicant killing cancer cell.
7. the purposes of peptide molecule as claimed in claim 5, this cancer medical composition can act synergistically with chemotherapeutic agent, suppresses the quantity of resistant cancer cells.
8. the antibody of isolated or purified or an antibody for artificial production, can be combined with peptide molecule as described below:
Comprise the peptide molecule of at least one in SEQ ID NO:1 sequence, SEQ ID NO:2 sequence, SEQ ID NO:3 sequence, SEQ ID NO:4 sequence, SEQ ID NO:5 sequence, SEQ ID NO:6 sequence and SEQID NO:7 sequence or its combination.
9. the antibody of isolated or purified as claimed in claim 8 or the antibody of artificial generation, can promote the effect of natural killer cell toxicant killing cancer cell.
10. the antibody of isolated or purified as claimed in claim 8 or the antibody of artificial generations, can act synergistically with chemotherapeutic agent, the quantity of suppression resistant cancer cells.
11. 1 kinds are detected cover group, in order to detect the anti-body contg of the atp binding cassette transport protein in sample, comprise a peptide molecule in this detection cover group, and the aminoacid sequence of this peptide molecule comprises at least one in SEQ ID NO:1 sequence, SEQ ID NO:2 sequence, SEQ ID NO:3 sequence, SEQ ID NO:4 sequence, SEQ ID NO:5 sequence, SEQ ID NO:6 sequence and SEQ ID NO:7 sequence or its combination.
12. 1 kinds of detection methods, system is using a peptide molecule as a probe, detect the anti-body contg of the atp binding cassette transport protein in a sample, wherein the aminoacid sequence of this peptide molecule comprises at least one in SEQID NO:1 sequence, SEQ ID NO:2 sequence, SEQ ID NO:3 sequence, SEQ ID NO:4 sequence, SEQ ID NO:5 sequence, SEQ ID NO:6 sequence and SEQ ID NO:7 sequence or its combination.
13. detection methods as claimed in claim 12, system utilizes at least one of ferment immunoabsorption, Western blot, biochip method, Beads enrichment and quantitative manner and other probe in detecting modes, detects the anti-body contg of the atp binding cassette transport protein in this sample.
14. detection methods as claimed in claim 12, it at least comprises the following steps:
A () applies in this peptide molecule to one container;
B () removes the first suspension in this container;
C () inserts one of this sample proper concn sample in this container;
D () removes the second suspension in this container;
E () inserts a second antibody;
F () removes the 3rd suspension in this container; And
G () detects the content of this second antibody in this container.
15. detection methods as claimed in claim 14, wherein this container system 96 porose disc.
16. detection methods as claimed in claim 12, wherein this sample system is separated at least one in one of human body blood, a blood plasma or a serum.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW102135112 | 2013-09-27 | ||
| TW102135112 | 2013-09-27 | ||
| TW103127229 | 2014-08-08 | ||
| TW103127229A TWI534154B (en) | 2013-09-27 | 2014-08-08 | Peptides for selecting anti-cancer pharmaceutical composition and the application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104513297A true CN104513297A (en) | 2015-04-15 |
| CN104513297B CN104513297B (en) | 2018-12-04 |
Family
ID=52789191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410417537.8A Expired - Fee Related CN104513297B (en) | 2013-09-27 | 2014-08-22 | Polypeptide molecule for screening anti-cancer pharmaceutical composition and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2015067611A (en) |
| CN (1) | CN104513297B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018050066A1 (en) * | 2016-09-14 | 2018-03-22 | 北京大学 | Abcg2 monoclonal antibody and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7785812B2 (en) * | 1997-04-16 | 2010-08-31 | Millennium Pharmaceuticals, Inc. | Multidrug resistance-associated polypeptide |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2820384A1 (en) * | 2010-12-06 | 2012-06-14 | Cure Cancer Worldwide Corporation | Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer |
-
2014
- 2014-08-22 CN CN201410417537.8A patent/CN104513297B/en not_active Expired - Fee Related
- 2014-09-19 JP JP2014191706A patent/JP2015067611A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7785812B2 (en) * | 1997-04-16 | 2010-08-31 | Millennium Pharmaceuticals, Inc. | Multidrug resistance-associated polypeptide |
Non-Patent Citations (2)
| Title |
|---|
| 陈巧林等: "α-胞衬蛋白抗原多肽的筛选及其在干燥综合征临床诊断中的意义", 《中国免疫学杂志》 * |
| 黄九九等: "肿瘤多药耐药性中的ABC转运蛋白及其调节", 《现代生物医学进展》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018050066A1 (en) * | 2016-09-14 | 2018-03-22 | 北京大学 | Abcg2 monoclonal antibody and uses thereof |
| US10611847B2 (en) | 2016-09-14 | 2020-04-07 | Peking University | ABCG2 monoclonal antibody and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104513297B (en) | 2018-12-04 |
| JP2015067611A (en) | 2015-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11396547B2 (en) | Anti-EGFR and anti-CD3 bispecific antibody and uses thereof | |
| CN109400713B (en) | Use of novel chimeric antigen receptor modified T cells for the treatment of cancer | |
| CN110272490B (en) | Targeted CTLA-4 antibody, preparation method and application thereof | |
| EP3882276A1 (en) | Bispecific antibody, preparation method therefor and application thereof | |
| CN110330550B (en) | Affinity peptide of PD-L1-IgV and application thereof | |
| WO2022048640A1 (en) | Il-2 mutant and application thereof | |
| CN114621345A (en) | anti-LAG-3 monoclonal antibody, antigen binding fragment thereof and application thereof | |
| CN115698081A (en) | Chimeric antigen receptor targeting BCMA and uses thereof | |
| CN117069842B (en) | Anti-human BCMA nanobody with specific isoelectric point, CAR-T and application | |
| CN117126280B (en) | Anti-human BCMA nanobody with hydrophilic amino acid residues, CAR-T and application | |
| WO2021139761A1 (en) | Peptide having affinity to pd-1 and application thereof | |
| US20220127375A1 (en) | Producing compositions comprising two or more antibodies | |
| CN104513297A (en) | Polypeptide molecule for screening anti-cancer pharmaceutical composition and application thereof | |
| US20230091895A1 (en) | Nanobody for pcsk9 and application thereof | |
| CN105601746B (en) | Fusion protein of chimeric Fc receptor and preparation method and application thereof | |
| CN112501192B (en) | Hybridoma cell strain for generating anti-human IL21 monoclonal antibody and application thereof | |
| WO2022022719A1 (en) | TRUNCATED BODY OF IL7Rα AND USE THEREOF IN PREPARATION OF MEDICATION FOR TREATING TUMOR | |
| CN114617961B (en) | Injection preparation of anti-LAG-3 monoclonal antibody | |
| CN104961833B (en) | A kind of people source NKp80-Fc fusion proteins and preparation method thereof and the application in oncotherapy | |
| CN104513303A (en) | Polypeptide molecule for screening anti-cancer pharmaceutical composition and application thereof | |
| Zhong et al. | T cell stimulation and expansion by SunTag-based clustering of anti-CD3/CD28 scFv | |
| CN106084042B (en) | Fully human anti-MAGEA 1 full-molecular IgG antibody and application thereof | |
| CN113308491B (en) | Recombinant plasmid and recombinant cell for co-expressing NFAT and human DNAM-1 protein, and construction method and application thereof | |
| CN116023500B (en) | Chimeric antigen receptor targeting fully humanized CD70 and application thereof | |
| CN116239690B (en) | anti-CD 123 nano antibody and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20181204 Termination date: 20210822 |